(VIANEWS) – The NASDAQ opens in less than two hours and Catalyst Pharmaceuticals‘s pre-market value is already 11.54% down.
Catalyst Pharmaceuticals’s last close was $20.80, 5.92% below its 52-week high of $22.11.
The last session, NASDAQ finished with Catalyst Pharmaceuticals (CPRX) jumping 2.61% to $20.80. NASDAQ rose 2.66% to $11,140.43, following the last session’s upward trend on what was an all-around up trend trading session.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.71.
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 29.29. Meaning,
the purchaser of the share is investing $29.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.35%.
Annual Top and Bottom Value
Catalyst Pharmaceuticals’ stock price is $20.80 as of 08:27 EST. This value is below its 52 week high of $22.11 but well above its 52 week low of $5.24.
Today’s last reported volume for Catalyst Pharmaceuticals is 1915762 which is 60.79% below its average volume of 2358970.
Growth Estimates Quarters
For the current quarter, the company expects to grow by 122.2% and 166.7% respectively.
Catalyst Pharmaceuticals’s worth is way above its 50-day moving average of $17.12 and way higher than its 200-day moving average of $11.88.
More news about Catalyst Pharmaceuticals (CPRX).